Shots:

• The P-III STYLE study involves assessing of Otezla 30mg bid vs PBO in moderate to severe plaque psoriasis patients in ratio (2:1) for 16 wks.- evaluating its safety and efficacy
• P-III STYLE study results(N=300): improvement in 1EP of the ScPGA response (clear (0)/almost (1)/at least (2-point reduction)) @16wks.; met 2EP of whole body itch with NRS scale@16wks.; no new safety signals identified
• Otezla 30 mg is an oral small molecule PDE4i specific for cAMP- indicated for treatment of moderate-to-severe plaque psoriasis

Ref: Celgene | Image: Knowledge Ecology International